Critical Contrast: Vivos Therapeutics (NASDAQ:VVOS) versus Minerva Neurosciences (NASDAQ:NERV)

Vivos Therapeutics (NASDAQ:VVOS) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings.

Profitability

This table compares Vivos Therapeutics and Minerva Neurosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-121.37%	-849.22%	-96.11%
Minerva Neurosciences	N/A	N/A	-35.62%

Valuation and Earnings

This table compares Vivos Therapeutics and Minerva Neurosciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44 million	0.69	-$21.17 million	($2.07)	-0.43
Minerva Neurosciences	N/A	N/A	-$293.42 million	($26.80)	-0.25

Vivos Therapeutics has higher revenue and earnings than Minerva Neurosciences. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Vivos Therapeutics has a beta of 6.93, meaning that its share price is 593% more volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of -0.19, meaning that its share price is 119% less volatile than the S&P 500.

Institutional and Insider Ownership

26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by insiders. Comparatively, 10.4% of Minerva Neurosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Vivos Therapeutics and Minerva Neurosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1	2	2	0	2.20
Minerva Neurosciences	1	1	1	0	2.00

Vivos Therapeutics currently has a consensus price target of $2.58, suggesting a potential upside of 188.35%. Minerva Neurosciences has a consensus price target of $10.50, suggesting a potential upside of 53.73%. Given Vivos Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Vivos Therapeutics is more favorable than Minerva Neurosciences.

Summary

Vivos Therapeutics beats Minerva Neurosciences on 7 of the 13 factors compared between the two stocks.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

About Minerva Neurosciences

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.